Immune escape mechanisms in ALCL

Journal of Clinical Pathology

Volumn 56, Issue 6, 2003, Pages 423-425

  Oudejans, J J ^a   Ten Berge, R L ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; FAS ANTIGEN; GRANZYME B; PROTEIN BCL 2; SERINE PROTEINASE INHIBITOR;

ANAPLASTIC CARCINOMA; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; APOPTOSIS; CELL DEATH; CELL KILLING; CLONAL ANERGY; CYTOTOXIC LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA STRAND BREAKAGE; DOWN REGULATION; EDITORIAL; IMMUNOMODULATION; LARGE CELL LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

EID: 0038309633     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.6.423     Document Type: Editorial

References (33)

1. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organisation classification of tumours. Lyon: IARC Press, 2001.
2. ten Berge RL, Dukers DF, Oudejans J J, et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999;93:2688-96.
3. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697-706.
4. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-21.
5. Pulford K, Falini B, Banham AH, et al. Immune response to the ALK tyrosine kinase in patients with anaplastic large cell lymphoma. Blood 2000;96:1605-7.
6. Passoni L, Scardino A, Bertazzoli C, et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002;99:2100-6.
7. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al. MUC1 (EMA)is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001;54:933-9.
8. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC 1-specific cytotoxic T-lymphocytes. Cancer Res 2001;61:6846-50.
9. Los M, Herr I, Friesen C, et al. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-29.
10. Frisan T, Zhang QJ, Levitskaya J, et al. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer 1996;68:251-8.
11. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression in Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus positive and negative Hodgkin's disease. Blood 1996;87:3844.
12. Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998;92:2477-83.
13. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 1994;145:37-41.
14. Becker JC, Czerny C, Brocker EB. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 1994;6:1605-12.
15. Boulland ML, Meignin V, Leroy-Viard K, et al. Human interleukin-10 expression in T/natural killer-cell lymphomas. Association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 1998;153:1229-37.
16. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage co-stimulatory function. J Immunol 1992;148:3133-9.
17. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
18. O'Connell J, Bennett MW, O'Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
19. Mullauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 1998;11;369-75.
20. Ng CS, Lo ST, Chan JK. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. Hum Pathol 1999;30:48-53.
21. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
22. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998;273:27084-90.
23. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781-828.
24. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995;377:446-8.
25. Atkinson EA, Barry M, Darmon AJ, et al. Cytotoxic T-lymphocyte assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B. J Biol Chem 1998;273:21261-6.
26. Griffiths GM. The cell biology of CTL killing Curr Opin Immunol 1995;7:343.
27. Bird CH, Sutton VR, Sun J, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated opoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998;18:6387-98.
28. Sun J Bird CH, Sutton V, et al. A cytosolic granzyme B inhibitor related to the vira apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996;271:27802-9.
29. Bladergroen BA, Meijer CJLM, ten Berge RL, et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism For tumor cells to circumvent the immune system? Blood 2002;99:232-7.
30. Rassidakis GZ, Sarris AH, Herling M, et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001;159:527-35.
31. ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression levels of apoptosis related proteins predict clinical outcome in anaplastic marge cell lymphoma. Blood 2002;99:4540-6.
32. Zoi-Toli O, Vermeer MH, De Vries E, et al. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000;143:313-19.
33. Medema JP, de Jong J, van Hall T, et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999;190:1033-8.